Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis.

Molecular markers can improve staging and predict aggressive clinical behavior in esophageal cancer, thus helping to define appropriate therapeutic protocols and to identify patients who will benefit from surgery. We therefore characterized, by Northern blot and/or immunohistochemistry, the relative expression of three effectors involved in the invasion, angiogenesis, and dissemination of tumor cells in esophageal cancer versus nontumoral mucosae: (a) stromelysin-3 (ST3), a member of the metalloproteinase family; (b) basement membrane 40/secreted protein acidic and rich in cysteine (BM-40/SPARC), an extracellular matrix-associated protein involved in angiogenesis; and (c) the hepatocyte growth factor receptor MET, which triggers the scattering of epithelial cells. Results were analyzed in relation to clinicopathological parameters (cpTNE) including tumor size (T), lymph node status (N), periesophageal tissue invasion (E), disease recurrence, and overall survival. The ST3, BM-40/SPARC, and MET genes were found to be overexpressed in tumor samples compared to control mucosa. BM-40/SPARC and MET mRNA levels were not linked to any one of the cpTNE, indicating that this overexpression occurs at an early stage of neoplastic progression. In contrast, ST3 expression, identified by immunohistochemistry in fibroblastic cells surrounding neoplastic islets, correlated with tumor size and periesophageal tissue invasion. Of the 36 patients studied, those with high ST3 levels had shorter disease-free survival than those with low levels, but there was no relationship between the cpTNE and disease recurrence or survival. Our study demonstrates that ST3, BM-40/SPARC, and MET are involved in different steps of esophageal carcinogenesis and that ST3 overexpression is a marker of aggressive clinical behavior. We conclude that in esophageal cancer, ST3 might help to assess survival and the risk of recurrence after surgical resection.

[1]  M. Shipp,et al.  Stromelysin-3 Is Induced in Tumor/Stroma Cocultures and Inactivated via a Tumor-specific and Basic Fibroblast Growth Factor-dependent Mechanism* , 1998, The Journal of Biological Chemistry.

[2]  M. Barbacid,et al.  Identification of Insulin-like Growth Factor-binding Protein-1 as a Potential Physiological Substrate for Human Stromelysin-3* , 1997, The Journal of Biological Chemistry.

[3]  M. Ivan,et al.  Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells , 1997, Oncogene.

[4]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[5]  K. Miyazawa,et al.  Hepatocyte Growth Factor Activator Inhibitor, a Novel Kunitz-type Serine Protease Inhibitor* , 1997, The Journal of Biological Chemistry.

[6]  O. Podhajcer,et al.  Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.

[7]  O. Podhajcer,et al.  The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. , 1997, The Journal of investigative dermatology.

[8]  M. Omary,et al.  Src activation in malignant and premalignant epithelia of Barrett's esophagus. , 1997, Gastroenterology.

[9]  E. Sage.  Terms of attachment: SPARC and tumorigenesis , 1997, Nature Medicine.

[10]  M. Duffy,et al.  High levels of stromelysin‐3 correlate with poor prognosis in patients with breast carcinoma , 1996, International Journal of Cancer.

[11]  M. Stella,et al.  Ets up-regulates MET transcription. , 1996, Oncogene.

[12]  M. Furihata,et al.  Determination of the prognostic significance of unscheduled cyclin A overexpression in patients with esophageal squamous cell carcinoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  K. Kim,et al.  Amplification of stromelysin-3 transcripts from carcinomas of the colon. , 1996, Human pathology.

[14]  M. Kitajima,et al.  Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Ruggero Montesano,et al.  Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review , 1996, International journal of cancer.

[16]  C. Angeletti,et al.  Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  J. Rubin,et al.  Hepatocyte Growth Factor (HGF)/NK1 Is a Naturally Occurring HGF/Scatter Factor Variant with Partial Agonist/Antagonist Activity* , 1996, The Journal of Biological Chemistry.

[18]  M. Kitajima,et al.  Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  J. Foidart,et al.  Stromelysin-3 expression promotes tumor take in nude mice. , 1996, The Journal of clinical investigation.

[20]  P. Comoglio,et al.  The HGF receptor family: unconventional signal transducers for invasive cell growth , 1996, Genes to cells : devoted to molecular & cellular mechanisms.

[21]  K. Miyazawa,et al.  Activation of Hepatocyte Growth Factor in the Injured Tissues Is Mediated by Hepatocyte Growth Factor Activator (*) , 1996, The Journal of Biological Chemistry.

[22]  H. Osugi,et al.  Expression of immunoreactive human hepatocyte growth factor in human esophageal squamous cell carcinomas. , 1995, Cancer letters.

[23]  P. Basset,et al.  Characterization of monoclonal antibodies against stromelysin‐3 and their use to evaluate stromelysin‐3 levels in breast carcinoma by semi‐quantitative immunohistochemistry , 1995, International journal of cancer.

[24]  M. Shipp,et al.  Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. , 1995, Cancer research.

[25]  P. Chambon,et al.  Developmental expression of mouse stromelysin-3 mRNA. , 1995, Development.

[26]  T. Nakajima,et al.  Preoperative assessment of lymph nodes in the prediction of disease spread and outcome in cancer of the thoracic oesophagus , 1995, The British journal of surgery.

[27]  P. Chambon,et al.  Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin‐3 and BM‐40/SPARC genes , 1995, International journal of cancer.

[28]  B. Nordlinger,et al.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  M. Folkman,et al.  Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca2+‐binding EF‐hand sequence , 1995, Journal of cellular biochemistry.

[30]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. , 1994, The Journal of biological chemistry.

[31]  S. Weiss,et al.  Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. , 1994, The Journal of biological chemistry.

[32]  M. Bäckdahl,et al.  Correlation between stromelysin‐3 mRNA level and outcome of human breast cancer , 1994, International journal of cancer.

[33]  Michael S. Pepper,et al.  Membrane proteases in focus , 1994, Nature.

[34]  H. Sue-Ling,et al.  An audit of the treatment of cancer of the oesophagus. , 1994, Gut.

[35]  M. Iruela-Arispe,et al.  SPARC is a source of copper-binding peptides that stimulate angiogenesis , 1994, The Journal of cell biology.

[36]  J. Roder,et al.  Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus , 1994, The British journal of surgery.

[37]  J. Voorhees,et al.  Increased expression of stromelysin‐3 in basal cell carcinomas , 1994, Molecular carcinogenesis.

[38]  P. Robbins,et al.  Stromelysin‐3 expression in breast cancer biopsies: Clinico‐pathological correlations , 1993, International journal of cancer.

[39]  Z. Werb,et al.  SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway , 1993, The Journal of cell biology.

[40]  E Medico,et al.  Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  E. Sage,et al.  Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts , 1993, Journal of cellular physiology.

[42]  W. Birchmeier,et al.  Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. , 1992, The EMBO journal.

[43]  W. Birchmeier,et al.  A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Chambon,et al.  Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. , 1992, The Journal of investigative dermatology.

[45]  L. Naldini,et al.  Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth , 1992, The Journal of cell biology.

[46]  M. Iruela-Arispe,et al.  Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. , 1992, The Journal of biological chemistry.

[47]  E Medico,et al.  Expression of the Met/HGF receptor in normal and neoplastic human tissues. , 1991, Oncogene.

[48]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[49]  S. Weiss,et al.  Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity. , 1991, The Journal of clinical investigation.

[50]  L. Naldini,et al.  The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation , 1991, Molecular and cellular biology.

[51]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[52]  A. Mannell,et al.  Evaluation of the results of oesophagectomy for oesophageal cancer , 1991, The British journal of surgery.

[53]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[54]  J Vandekerckhove,et al.  Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells , 1990, The Journal of cell biology.

[55]  K. Sugimachi,et al.  Multivariate approach for assessing the prognosis of clinical oesophageal carcinoma , 1988, The British journal of surgery.

[56]  R. Timpl,et al.  Cloning and complete amino acid sequences of human and murine basement membrane protein BM‐40 (SPARC, osteonectin) , 1988, FEBS letters.

[57]  W. Eijkenboom,et al.  Survival after resection for carcinoma of the oesophagus , 1987, The British journal of surgery.

[58]  M. Mareel,et al.  Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion. , 1997, British Journal of Cancer.

[59]  S. Meltzer.  The molecular biology of esophageal carcinoma. , 1996, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[60]  V. Castronovo,et al.  Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. , 1995, The American journal of pathology.

[61]  Catherine,et al.  Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. , 1993, Cancer research.